Side-by-side · Research reference

CagrilintidevsGonadorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED35/64 cited

BFDA-ApprovedHUMAN-REVIEWED7/61 cited

Cagrilintide

Long-Acting Amylin Analogue · Phase 3

7.5%Additional weight loss vs semaglutideAhmed 2026

Once weeklyDosing frequencyBailey 2026

Dual AMYR/CTRReceptor agonismBailey 2026

SQ · Once WeeklyBailey 2026

Gonadorelin

GnRH Analogue · Diagnostic & Therapeutic

90 minPulsatile interval

73%Ovulation restorationTadesse 2026

2–4 minPlasma half-life

IV / SQ · Pulsatile Pump (Therapeutic) · Single Bolus (Diagnostic)

01Mechanism of Action

Parameter

Cagrilintide

Gonadorelin

Primary target

Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026

GnRH receptors on anterior pituitary gonadotropes

Pathway

AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026

GnRH → Pituitary gonadotrope → LH/FSH secretion → Gonadal steroidogenesisSharma 2026

Downstream effect

Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026 Yamauchi 2026

Pulsatile LH/FSH release stimulates testicular testosterone or ovarian estradiol/progesterone synthesis; initiates folliculogenesis and spermatogenesisRobin 2026 Sharma 2026

Feedback intact?

Yes — acts via physiological amylin pathways

Yes — pulsatile delivery preserves negative feedback loops; continuous exposure desensitizes receptors

Origin

Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026

Synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) identical to native hypothalamic GnRH

Antibody development

—

02Dosage Protocols

Parameter

Cagrilintide

Gonadorelin

Standard dose (combination)

Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026

Phase 3 REDEFINE 5 trial dosing.

—

Monotherapy dosing

Dose-dependent, under investigation

Monotherapy trials reported in meta-analysis.

—

Frequency

Once weekly (subcutaneous)Bailey 2026

Long-acting formulation.

—

Evidence basis

Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026 Ahmed 2026

RCT / Expert consensus

Duration

26–52 weeks in trialsYamauchi 2026

Continuous until pregnancy achieved or fertility goals met

3–6 month courses typical for ovulation induction.

Route

Subcutaneous injectionBailey 2026

IV preferred (therapeutic) · SQ acceptable (diagnostic)

Diagnostic test (pituitary function)

—

100 mcg IV or SQ bolus

Measure baseline LH/FSH, then 30/60/90 min post-injection. Normal response: LH ≥2× baseline.

Therapeutic (hypothalamic hypogonadism)

—

5–20 mcg IV bolus every 90–120 minutes

Requires portable pulsatile pump. Dose individualized to achieve normal gonadotropin pulsatility.Robin 2026

Pulsatile interval

—

90 minutes (females) · 120 minutes (males)

Mimics physiological GnRH pulse frequency.

Half-life

—

2–4 minutes (plasma)

Necessitates frequent pulsatile administration.

Alternative protocols

—

Exogenous gonadotropins (hCG/hMG) often preferred due to convenience vs pump requirement

03Metabolic / Fat Loss Evidence

Parameter

Cagrilintide

Gonadorelin

Weight loss vs semaglutide

7.47% greater percentage weight lossAhmed 2026

CagriSema combination vs semaglutide monotherapy (meta-analysis).

—

Absolute weight change

Significantly greater absolute weight reductionAhmed 2026

Mean difference favoring combination therapy.

—

Mechanism

Central satiety inductionBailey 2026

—

BMI reduction

Significant BMI reduction vs comparatorAhmed 2026

—

Glycemic benefit

Reduced fasting glucose and HbA1cAhmed 2026

Synergistic effect with semaglutide in combination.

—

Lipid effects

Improvements in total cholesterol, LDL-C, HDL-C, VLDL-C, triglyceridesAhmed 2026

—

Body composition

Predominant fat loss with weight reduction

—

Mitochondrial function

In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026

C2C12 myotube study; clinical relevance under investigation.

—

Combination rationale

Multi-pathway approach: amylin (satiety) + GLP-1 (incretin)Lempesis 2026

—

Key publications

REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026 Ahmed 2026 Bailey 2026

—

Fat loss mechanism

—

None — gonadorelin acts exclusively on reproductive axis

Indirect metabolic effects

—

Restoration of sex hormones may normalize body composition in hypogonadal states

Effect mediated by downstream testosterone/estradiol, not GnRH itself.

04Side Effects & Safety

Parameter

Cagrilintide

Gonadorelin

Gastrointestinal

Nausea, diarrhea (common with incretin-based therapies)Pardali 2026

Dietary management and nutritional monitoring recommended.

—

Injection site reactions

Local reactions possible with subcutaneous administration

—

Safety profile

Generally consistent with incretin-based therapies

Phase 3 and meta-analysis safety data.

—

Tolerability

Tolerability considerations similar to GLP-1RAs

—

Muscle preservation

Lean mass considerations during weight loss

In vitro mitochondrial effects observed; clinical impact under investigation.

—

Injection site reaction

—

Erythema, irritation (pulsatile pump catheter site)

Headache

—

Common with bolus administration

Nausea / abdominal discomfort

—

Transient, dose-related

Ovarian hyperstimulation syndrome (OHSS)

—

Risk with ovulation induction protocols; monitor follicular development via ultrasound

Multiple gestation

—

Increased risk with fertility protocols (twins ~10–15%)

Anaphylaxis

—

Rare hypersensitivity reaction

Pump malfunction / infection

—

Mechanical failure or catheter-site infection with long-term IV pump use

Receptor desensitization

—

Continuous (non-pulsatile) exposure paradoxically suppresses gonadotropinsRobin 2026

Absolute Contraindications

Cagrilintide

·Hypersensitivity to cagrilintide or formulation components

Gonadorelin

·Pregnancy (except therapeutic infertility protocols)
·Hypersensitivity to gonadorelin or excipients
·Hormone-dependent tumors (prostate, breast) — risk of tumor stimulation via sex hormone elevation

Relative Contraindications

Cagrilintide

·Severe gastrointestinal disease
·History of pancreatitis (incretin-based therapy consideration)

Gonadorelin

·Ovarian cysts or PCOS (monitor for OHSS)
·Pituitary adenoma or other sellar mass (may worsen with gonadotropin surge)

05Administration Protocol

Parameter

Cagrilintide

Gonadorelin

1. Dosing frequency

Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026

Administer 100 mcg IV or SQ bolus. Draw baseline LH/FSH, then at 30, 60, 90 minutes. Normal response: LH ≥2× baseline, FSH modest rise. Blunted response suggests pituitary pathology; exaggerated response may indicate primary hypogonadism.

2. Combination form

Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026 Bailey 2026

Requires programmable infusion pump with IV catheter. Set pulse interval to 90 min (females) or 120 min (males). Bolus dose 5–20 mcg per pulse. Pump worn continuously; catheter site rotated every 48–72 hrs to prevent infection.

3. Injection site

Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.

Lyophilised gonadorelin reconstituted with sterile saline or provided diluent. Typically 0.8–3.2 mg dissolved in 8 mL for pump reservoir. Solution stable 7–14 days refrigerated.

4. Storage

Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.

For fertility protocols: ultrasound follicular tracking + serial estradiol/LH measurements. Adjust pulse dose to achieve mid-follicular LH 5–10 IU/L. Ovulation confirmed by progesterone rise or ultrasound.

5. Dietary considerations

Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026

Pulsatile therapy initiated at any point in cycle. Diagnostic test performed in morning (higher baseline LH). For ovulation induction, treatment begins early follicular phase.

06Stack Synergy

Cagrilintide

+ Semaglutide

Strong

View Semaglutide →

Cagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.

CagriSema: Cagrilintide 2.4 mg + Semaglutide 2.4 mg
Frequency: Once weekly subcutaneous
Duration: 26–52 weeks (trial data)
Primary benefit: Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation

Yamauchi 2026 Ahmed 2026 Bailey 2026

Gonadorelin

+ hCG (Human Chorionic Gonadotropin)

Multi-pathway

View hCG (Human Chorionic Gonadotropin) →

In hypogonadotropic hypogonadism protocols, gonadorelin restores pituitary LH/FSH pulsatility, while exogenous hCG directly stimulates Leydig cells (acting as LH mimetic) to maintain testosterone production. This dual approach ensures both central axis restoration and immediate gonadal steroidogenesis, preventing testicular atrophy during fertility treatment. hCG's longer half-life (24–36 hrs) complements gonadorelin's pulsatile short-acting profile.

Gonadorelin: 5–10 mcg IV every 120 min (pulsatile pump)
hCG: 1500–2000 IU SQ · 2–3× per week
Duration: 12–24 weeks for spermatogenesis induction
Primary benefit: Fertility restoration in hypothalamic hypogonadism with maintained testicular function